Bank of New York Mellon Corp Takes Position in Edwards Lifesciences Corporation $EW

Key Points

• Bank of New York Mellon acquired 14.08 million Edwards Lifesciences shares worth approximately $1.27 billion, giving it a 2.45% stake. Institutional investors collectively own 79.46% of the company.
• Analysts maintain a positive outlook, with a consensus “Moderate Buy” rating and an average price target of $100.27; 17 analysts rate the stock Buy versus six Holds.
• Edwards reported quarterly EPS of $0.78, beating estimates of $0.74, while revenue rose 13.6% year over year to $1.74 billion. The stock opened at $90.02 and trades near the middle of its 12-month range.

Bank of New York Mellon Corp bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 14,084,483 shares of the medical research company's stock, valued at approximately $1,274,082,000. Bank of New York Mellon Corp owned 2.45% of Edwards Lifesciences at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of EW. Hanson & Doremus Investment Management bought a new stake in Edwards Lifesciences during the first quarter valued at approximately $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter valued at $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $27,000. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company's stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company's stock, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on EW shares. Truist Financial upped their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research report on Thursday, July 16th. Citigroup raised their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. Robert W. Baird lifted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a "neutral" rating in a research note on Friday, April 24th. Leerink Partners upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Finally, Mizuho increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Edwards Lifesciences Stock Performance

NYSE EW opened at $90.02 on Friday. The company has a 50-day simple moving average of $89.12 and a two-hundred day simple moving average of $84.63. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The firm has a market cap of $51.83 billion, a price-to-earnings ratio of 51.74, a PEG ratio of 2.32 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. During the same period last year, the firm earned $0.67 earnings per share. The company's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source